

## 17 TEVA PHARMA

5 Basel St., P.O. Box 3190, Petach Tikva, 49131 Israel  
Tel: (972) 3-926-7267 Fax: (972) 3-926-7472  
www.tevapharm.com

<b>HEADCOUNT</b>	38,307
<b>YEAR ESTABLISHED</b>	1944
<b>PHARMA REVENUES*</b>	\$10,482 +18%
<b>TOTAL REVENUES</b>	\$11,085 +18%
<b>NET INCOME</b>	\$635 -67%
<b>R&amp;D BUDGET</b>	\$786 +35%

\* Does not include \$603 million in API sales

### DRUGS APPROVED/LAUNCHED

<i>Drug</i>	<i>Indication</i>
Copaxone	multiple sclerosis

### DRUGS IN PHASE IIB AND BEYOND

<i>Drug</i>	<i>Indication</i>
Laquinimod	relapsing multiple sclerosis
stem ex	hemato-oncological indications
Adagio	delayed progression of Parkinson's disease

### EARLY RESEARCH PROJECTS

<i>Drug</i>	<i>Indication</i>
Laquinimod	Crohn's disease, lupus nephritis
tv-3813	psoriasis

### TOP SELLING DRUGS

<i>Drug</i>	<i>Indication</i>	<i>\$</i>	<i>(+/- %)</i>
Copaxone	MS	\$2,260	32%
Azilect	Parkinson's disease	\$175	46%
Respiratory (non-generic)		\$778	5%
Biogenerics		\$63	26%

Account for 31% of total pharma sales, up from 30% in 2007.

## 18 ASTELLAS

3-11, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, Japan 103-8411  
Tel: (81) 3 3244 3000 Fax: (81) 3 3244 3272  
www.astellas.com

<b>HEADCOUNT</b>	14,261
<b>YEAR ESTABLISHED</b>	2005
<b>PHARMA REVENUES</b>	\$9,646 +13%/-1%*
<b>TOTAL REVENUES</b>	\$9,657 +13%/-1%*
<b>NET INCOME</b>	\$1,710 +10%/-4%*
<b>R&amp;D BUDGET</b>	\$1,591 +35%/+18%*

\* converted at avg. exch. rate / based on local currency (JPY)

### DRUGS APPROVED/LAUNCHED

<i>Drug</i>	<i>Indication</i>
Prograf	organ rejection in kidney transplant
Irribow	irritable bowel syndrome (Japan)
Graceptor	organ rejection, graft rejection (Japan)
Mycamine	invasive candidiasis (EU)

### DRUGS PENDING APPROVAL

<i>Drug</i>	<i>Indication</i>
Pprograf	all myasthenia gravis, ulcerative colitis (Japan)
fk506	organ rejection - modified release (U.S.)

### DRUGS IN PHASE IIB AND BEYOND

<i>Drug</i>	<i>Indication</i>
conivaptan	hyponatremia, acute decompensated heart failure

aps1585 chronic kidney disease  
ym443 dyspepsia

### DRUGS COMING OFF PATENT

<i>Drug</i>	<i>Indication</i>
Vaprisol	hyponatremia (2010)

### TOP SELLING DRUGS

<i>Drug</i>	<i>Indication</i>	<i>\$</i>	<i>(+/- %)</i>
Prograf	transplantation	\$2,010	13%
Harnal	BPH	\$1,166	8%
Lipitor	cholesterol	\$953	11%
Vesicare	bladder	\$714	35%
Micardis	hypertension	\$644	17%
Gaster	acid reflux	\$530	-1%

Account for 62% of total pharma sales, same as in 2007.

## 19 DAIICHI SANKYO

3-5-1 Nihombashi-honcho, Chuo-ku, Tokyo, 103-8426 Japan

Tel: (81) 3 6255 1111 Fax: (81) 3 5255 7035

www.daiichisankyo.com

<b>HEADCOUNT</b>	28,895	
<b>YEAR ESTABLISHED</b>	2005	
<b>PHARMA REVENUES</b>	\$7,900	+7%/-6%*
<b>TOTAL REVENUES</b>	\$8,421	+9%/-4%*
<b>NET LOSS</b>	\$2,155	n/a
<b>R&amp;D BUDGET</b>	\$1,845	+29%/+13%*

\* converted at avg. exch. rate / based on local currency (JPY)

### DRUGS APPROVED/LAUNCHED

Drug	Indication
Azor	hypertension - 1st line (U.S.)
Efient	prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (PCI) (EU)
Welchol	reduce blood glucose in adults with type 2 diabetes (U.S.)

### DRUGS PENDING APPROVAL

Drug	Indication
prasugrel	acute coronary syndrome (with Lilly)

### DRUGS IN PHASE IIB AND BEYOND

Drug	Indication
cs-011 (rivoglitazone)	diabetes

cs-8635	cardiovascular disease
du-176b	atrial fibrillation

### DRUGS IN PHASE IIB AND BEYOND

Drug	Indication
cs-7017	oncology
cs-0777	immunosuppressive
db-772d	oral factor Xa inhibitor
cs-8080	anti-arteriosclerosis
sun-13834	chymase inhibitor

### TOP SELLING DRUGS

Drug	Indication	\$	(+/- %)
Olmesartan	hypertension	\$2,111	23%
Levofloxacin	anti-infection	\$977	2%
Pravastatin	cholesterol	\$608	-9%

Account for 47% of total pharma sales, up from 45% in 2007.

## 20 EISAI

4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 112-8088, Japan

Tel: (81) 3 3817 3700 Fax: (81) 3 3811 3077

www.eisai.co.jp

<b>HEADCOUNT</b>	10,000+	
<b>YEAR ESTABLISHED</b>	2005	
<b>PHARMA REVENUES</b>	\$7,612	+22%/+7%*
<b>TOTAL REVENUES</b>	\$7,817	+21%/+6%*
<b>NET INCOME</b>	\$477	n/a
<b>R&amp;D BUDGET</b>	\$1,561	-21%/-31%*

\* converted at avg. exch. rate / based on local currency (JPY)

### DRUGS APPROVED/LAUNCHED

Drug	Indication
Banzel	adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (U.S.)
Ontak	cutaneous T-cell lymphoma (U.S.)
Aloxi	prevention of chemotherapy-induced nausea and vomiting (U.S.)
Aciphex	GERD in adolescents ages 12 and above

### DRUGS PENDING APPROVAL

Drug	Indication
Rufinamide	epilepsy, partial-onset seizures
Aricept	severe Alzheimer's disease

### DRUGS IN PHASE IIB AND BEYOND

Drug	Indication
e5564	Critical care-severe sepsis

### EARLY RESEARCH PROJECTS

Drug	Indication
e5555	critical care-acute coronary syndrome
e7080	cancer - oral anti-cancer agent
e7974	cancer
e7820	cancer

### DRUGS COMING OFF PATENT

Drug	Indication
Aricept	Alzheimer's disease (2010)

### TOP SELLING DRUGS

Drug	Indication	\$	(+/- %)
Aricept	Alzheimer's disease	\$2,549	18%
Aciphex	acid reflux	\$1,545	4%

Account for 61% of total pharma sales, down from 65% in 2007.